---
title: Pfizer Vaccine Data Before FDA Panel
slug: 20201210-pfizer-vaccine-data-before-fda-panel
_id: 2bb431f4-6306-401f-a4aa-7919778621cf
_rev: p5oiLzuoOfR9bp21r1qvMz
type: quick_reads
draft: false
aliases:
  - /
_createdAt: '2021-03-31T18:54:31Z'
_updatedAt: '2021-04-01T05:36:08Z'
date: '2020-12-10T11:39:00.000Z'
lastmod: '2020-12-10T11:39:00.000Z'
weight: 50
featured_image:
  alt: Featured article image
  url: >-
    e5eee6b52e6cb65f5eb05412f87957005f9b2041367x367.jpg
card_series: Current Events
colorpaletteclassname: '--light-purple'
cards:
  - order: 0
    useCheckmark: false
    body: >-
      <div><p>New analysis on the first COVID-19 vaccine considered for
      Emergency Use Authorization by the FDA.</p><p>Here’s what we
      know.</p></div>
    _key: 2e3fca42a824
  - order: 1
    useCheckmark: false
    body: >-
      <div><h2>What It Is:</h2><ul><li>A two-dose Pfizer-BioNTech
      vaccine.</li><li>Developed using messenger RNA technology (mRNA); gives
      the body a genetic blueprint to build a viral protein in order to teach
      the body what to later identify and protect against.</li><li>Commonly
      called “the Pfizer vaccine,” though development started in early January
      by the founders of a German company, BioNTech, who feared COVID-19 would
      spread worldwide.</li></ul></div>
    _key: dcd85c7c1614
  - order: 2
    useCheckmark: false
    body: "<div><h2>Does It Work?</h2><p>Based on analysis released by the FDA:</p><ul><li>Early data\_suggests benefits after first dose and 95% efficacy of preventing COVID-19 after two doses.</li><li>“…suggested benefit of the vaccine in <strong>preventing severe COVID-19</strong>, in <strong>preventing COVID-19 following the first dose</strong>, and in <strong>preventing COVID-19 in individuals with prior SARS-CoV-2 infection</strong>…”</li></ul></div>"
    _key: f3b88a5a028b
  - order: 3
    useCheckmark: false
    body: >-
      <div><h2>Who Was Tested:</h2><ul><li>44,000 participants
      overall.</li><li>Ages range from 12 to 75 yrs old &amp;
      up.</li><li>Participants during Stage 1 <em>“excluded participants at high
      risk of SARS-CoV-2 infections.”</em></li><li>Phase 2/3 expanded to those
      higher risk, with preexisting conditions such as obesity and
      diabetes.</li><li>Phase 2/3 ratio of men:women was nearly even. Most
      participants (82%) were white. Median age: 51.</li></ul></div>
    _key: e0e5bca70b92
  - order: 4
    useCheckmark: false
    body: >-
      <div><h2>Safety</h2><blockquote>“….no specific safety concerns identified
      that would preclude issuance of an EUA.”<br><br>Data was gleaned from
      approx. 38,000 participants 16 years &amp; older over a median follow-up
      duration of two months after their second dose.</blockquote></div>
    _key: 48c3410f3470
  - order: 5
    useCheckmark: false
    body: >-
      <div><h2>What Reactions Did People Commonly Have?</h2><ul><li>injection
      site reactions (84.1%);</li><li>fatigue (62.9%);</li><li>headache
      (55.1%);</li><li>muscle pain (38.3%);</li><li>chills
      (31.9%);</li><li>joint pain (23.6%);</li><li>fever
      (14.2%).</li></ul><p>*Reactions were more prevalent in younger
      participants, rather than older.*</p><p><br></p></div>
    _key: 903b5067168a
  - order: 6
    useCheckmark: false
    body: >-
      <div><h2>PREGNANCY</h2><p>“Pregnancy outcomes are otherwise unknown at
      this time.”</p><ul><li>Women were given pregnancy tests before
      participating in trial and excluded if pregnant.</li><li>23 pregnancies
      occurred during trial (12 in women who received the vaccine, 11 in placebo
      group) and the study will be “collecting outcomes” of these
      pregnancies.</li></ul></div>
    _key: 7b481ead1f5c
  - order: 7
    useCheckmark: true
    body: >-
      <div><p>The mRNA technology used to create this vaccine has never been
      approved for use against infectious diseases or licensed in the United
      States -- for emergency use authorization (EUA) or otherwise. An advisory
      panel will recommend whether or not to grant EUA to this vaccine on
      Thursday Dec. 10.</p><p></p></div>
    citation: VIEW SOURCES
    _key: e20f7049cb7a

---
**Update** the panel voted to recommend emergency use authorization of this vaccine.

[https://www.fda.gov/media/144245/download](https://www.fda.gov/media/144245/download)

Here’s a rough outline of where we gathered our info:

Card 3: Page 6

Card 4: 12/19

Card 5: Page 6

Card 6: Page 6

Card 7: 42